←
Genmab1,388 posts
Genmab avatar

Genmab

@Genmab

International biotech company dedicated to improving the lives of people with cancer & other serious diseases through antibodies. gmab.ly/Jn0e50XWplA

◷ Joined December 2015▧ 975 Photos and videos
Genmab avatar
Genmab@Genmab·Nov 5

#InvestorUpdate: Genmab reported financial results for the first nine months of 2026. Watch our Q3 webcast for updates on our pipeline, strategic priorities and continued progress as an integrated biotech: edge.media-server.com/mmc/p/….

0:43
Genmab avatar
Genmab@Genmab·Nov 4

#NewsUpdate: We’re looking forward to #ASH26, where new and exciting clinical data will be shared. Our research will feature multiple abstracts highlighting our latest advances across various types of #BloodCancer. Learn more: genmab.com/news-insights

0:04
Genmab avatar
Genmab@Genmab·Nov 4

#InvestorUpdate | Mark your calendar for November 5: Genmab will release our interim report for the first nine months of 2026. Join us to learn about our strategic priorities, growth as an integrated biotech and progress in advancing innovative antibody medicines for patients. Register here: register-conf.media-server.c….

Post attachment
Genmab avatar
Genmab@Genmab·Oct 28

Today, we announced positive Phase 3 topline results for our investigational therapy in head and neck cancer. The findings reinforce the potential of our differentiated antibody science and reflect our continued commitment to developing transformative medicines for people living with cancer. Learn more: gmab.ly/2eLa5100ARh.

0:15
Genmab avatar
Genmab@Genmab·Oct 26

We shared new research in recurrent or metastatic head and neck squamous cell carcinoma (#HNSCC), a disease where significant needs remain, at @myESMO.(1) We are grateful to the investigators, study participants, and healthcare professionals who help to advance #AntibodyScience research for this patient community. Learn more: gmab.ly/2eLa5100ARh. #ESMO26 1. Ionna, et al. (2021). Recurrent/metastatic squamous cell carcinoma of the head and neck. Cancers, 13(10), Article 2371. doi.org/10.3390/cancers13102…

0:10
Genmab avatar
Genmab@Genmab·Oct 25

At @myESMO, we presented new research in metastatic colorectal cancer, where there remains a need for continued progress.(1) We are proud to stand alongside the oncology community in advancing the development of potential therapeutic options for people affected by cancer. Learn more: gmab.ly/2eLa5100ARh. #ESMO26 1. Ionna, et al. (2021). Recurrent/metastatic squamous cell carcinoma of the head and neck. Cancers, 13(10), Article 2371. doi.org/10.3390/cancers13102…

0:10
Genmab avatar
Genmab@Genmab·Oct 24

We’ve announced a clinical trial collaboration with @Incyte to evaluate a novel combination of investigational therapies with standard-of-care chemotherapy, reflecting our shared commitment to cancer research. Learn more: gmab.ly/2eLa5100ARh.

Post attachment
Genmab avatar
Genmab@Genmab·Oct 23

Today, we announced the first Phase 3 results for one of our investigational therapies in ovarian cancer. These data mark a milestone for our gynecologic cancer portfolio and build on our hope in its potential for patients living with ovarian cancer. Learn more: gmab.ly/2eLa5100ARh.

0:31
Genmab avatar
Genmab@Genmab·Oct 21

Welcome to a new edition of #AntibodyHour 🕙! Watch to hear our colleague Marcia Kruidhof, Clinical Trial Manager, share what motivates her, how collaboration helps teams find solutions, and what Genmab’s patient-focused approach to research means to her. #PatientFirst

1:23
Genmab avatar
Genmab@Genmab·Oct 19

En 2023, le cancer du col de l’utérus figure parmi les cancers les plus fréquents chez les femmes âgées de 15 à 44 ans en France.(3) Nous œuvrons à faire progresser l’innovation avec un objectif : contribuer à améliorer les résultats pour les patientes. #CervicalCancer #WomensHealth

0:19
Genmab avatar
Genmab@Genmab·Oct 14

We’re excited to attend this year’s @myESMO Congress and connect with experts in the field. To learn more about our pipeline of innovative antibodies, visit booth #8022 in Exhibit Hall 8 and click here: gmab.ly/mCNg50TkooM. #Oncology #ESMO2026

0:20
Genmab avatar
Genmab@Genmab·Oct 7

During this edition of #AntibodyHour 🕙, we spotlight our colleague Iris Kolder, Director, Translational and Clinical Data Science. Iris shares what motivates her work to bring medicines to patients, how she sees the people behind the data, and how her experience as a cancer survivor brings personal meaning to what she does each day. #AntibodyScience

1:22